We studied the impact of cytogenetics and kind of induction/consolidation therapy on 848 adult @entity3052 ( @entity3052 ) @entity1 (age 15-83). The @entity1 received three types of induction/consolidation regimen: standard ( @entity5699 and @entity2592 (3/7); two cycles); intensive ( @entity8779 , @entity2592 and @entity2879 (ICE), plus @entity2664 and intermediate-dose @entity2592 (NOVIA)); and low-dose (low-dose @entity2592 ). CR @entity1 under 60 years of age, if an HLA-identical donor was available received allogeneic stem cell transplantation (allo- @entity12497 ); otherwise, as part of the program, they underwent autologous (auto)- @entity12497 . CR rates significantly associated with 'favorable' (inv(16), t(8;21)), 'intermediate' ('no abnormality', abn(11q23), +8, @entity6158 )) and 'unfavorable' (del (5q), -7, abn(3)(q21q26), t(6;9), 'complex' (more than three unrelated @entity2008 )) karyotypes (88% vs 65% vs 36%, respectively; P = 0.0001). These trends were confirmed in all age groups. On therapeutic grounds, intensive induction did not determine significant increases of CR rates in any of the considered groups, with respect to standard induction. Low-dose induction was associated with significantly lower CR rates. Considering disease-free survival (DFS), multivariate analysis of the factors examined (including karyotype grouping) showed that only age > 60 years significantly affected outcome. However, in cases where intensive induction was adopted, 'favorable' karyotype was significantly related to longer DFS (P = 0.04). This was mainly due to the favorable outcome of t(8;21) @entity1 treated with intensive induction. @entity1 receiving allo- @entity12497 had significantly longer DFS (P = 0.005); in particular, allo- @entity12497 significantly improved DFS in the 'favorable' and 'intermediate' groups (P = 0.04 and P = 0.048, respectively). In conclusion our study could provide some guidelines for @entity3052 therapy: (1) @entity1 in the 'favorable' karyotype group seem to have a longer DFS when treated with an intensive induction/consolidation regimen, adopted before auto- @entity12497 instead of standard induction; this underlines the importance of reinforcement of chemotherapy, not necessarily based on repeated high-dose AraC cycles. Allo- @entity12497 , independently of induction/consolidation therapy, should be considered an alternative treatment; (2) @entity1 in the 'intermediate' karyotype group should receive allo- @entity12497 ; (3) @entity1 in the 'unfavorable' karyotype group should be treated using investigational chemotherapy, considering that even allo- @entity12497 cannot provide a significantly longer DFS, but only a trend to a better prognosis.

The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of XXXX --analysis of 848 @entity1 .

@entity1 :: ('9606', 'Species') :: ['patients', 'Patients'] @entity12497 :: ('MESH:C535780', 'Disease') :: ['SCT'] @entity5699 :: ('MESH:D003630', 'Chemical') :: ['daunorubicin'] @entity6158 :: ('100820631', 'Gene') :: ['del(7q'] @entity8779 :: ('MESH:D015255', 'Chemical') :: ['idarubicin'] @entity2664 :: ('MESH:D008942', 'Chemical') :: ['mitoxantrone'] @entity2592 :: ('MESH:D003561', 'Chemical') :: ['cytosine arabinoside', 'Ara-C'] @entity3052 :: ('MESH:D015470', 'Disease') :: ['acute myeloid leukemia', 'AML'] @entity2879 :: ('MESH:D005047', 'Chemical') :: ['etoposide'] @entity2008 :: ('MESH:D002869', 'Disease') :: ['cytogenetic abnormalities']
@entity3052 :: (MESH:D015470,Disease) :: ['acute myeloid leukemia']
